Tilia Fe Kit
Product Images NDC 75907-086

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Tilia Fe (NDC 75907-086). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Dr. Reddy�s Laboratories Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Carton (Carton)

Packaging label for Tilia Fe kit containing Norethindrone Acetate and Ethinyl Estradiol Tablets, USP and Ferrous Fumarate Tablets with strengths of 1 mg/0.02 mg, 1 mg/0.03 mg, and 1 mg/0.035 mg. The label shows dosage form as tablets, the labeler as Dr. Reddy's Laboratories Inc., and includes three blister cards of 28 tablets each. It features usage notes and storage instructions, along with a barcode.*

FDA Label Image

Fig1 (Fig1(1))

Two line graphs depicting mean steady-state plasma concentrations of Ethinyl Estradiol and Norethindrone over 24 hours after chronic administration of Norethindrone Acetate and Ethinyl Estradiol tablets. The left graph shows Ethinyl Estradiol concentration (pg/mL) decreasing over time, and the right graph shows Norethindrone concentration (ng/mL) similarly decreasing, with data points for three different dosage ratios (1/20, 1/30, 1/35).*

FDA Label Image

Fig2 (Fig2(1))

A line graph showing the mean percent reduction in total lesion counts over six 28-day cycles for the intent-to-treat population. The graph compares norethindrone acetate and ethinyl estradiol (NDAc/EE) tablets versus placebo. Both groups show gradual lesion count reduction, with NDAc/EE tablets showing a slightly greater decrease by cycle 6. A table below the graph lists mean total lesion counts for NDAc/EE tablets and placebo at each cycle.*

FDA Label Image

Fig3 (Fig3(1))

A bar chart showing circulatory disease mortality rates per 100,000 woman years categorized by age groups (15-24, 25-34, 35-44, 45+), smoking status, and combined oral contraceptive use. Mortality rates are represented for four groups: ever-users (non-smokers), ever-users (smokers), controls (non-smokers), and controls (smokers).*

FDA Label Image

Fig4 (Fig4(1))

A horizontal forest plot titled 'Relevant Studies of Risk of Breast Cancer with Combined Oral Contraceptives' comparing ever use vs. never use and current use vs. never use across several cohort studies. The plot shows effect estimates (OR, RR, HR) with confidence intervals for each study along the effect estimate axis ranging from -1.5 to 2.0, with a reference line at 1.0.*

FDA Label Image

Fig5 (Fig5)

An instructional illustration showing how to use the Tilia Fe tablet kit. It includes a hand placing a day label sticker over the days of the week on the kit, instructions for day 1 starters and Sunday starters, and a key for the tablet colors and quantities: pale yellow (5 active tablets), light yellow (7 active tablets), light brown (9 active tablets), and brown (7 non-active tablets). Arrows indicate the direction to take the pills from left to right.*

FDA Label Image

Fig6 (Fig6)

A data table showing the annual number of birth-related or method-related deaths associated with control of fertility per 100,000 nonsterile women by fertility control method according to age groups 15-19, 20-24, 25-29, 30-34, 35-39, and 40-44. The table includes methods such as no fertility control, oral contraceptives for smokers and non-smokers, IUD, condom, diaphragm/spermicide, and periodic abstinence, with deaths categorized as birth-related or method-related where indicated.*

FDA Label Image

Table1 (Table1)

Table presenting mean and standard deviation steady-state pharmacokinetic parameters of norethindrone acetate and ethinyl estradiol tablets. It includes maximum plasma concentration (Cmax), area under the curve (AUC), apparent oral clearance (CL/F), and sex hormone-binding globulin (SHBG) values at different dose ratios and cycle days.*

FDA Label Image

Table4 (Table4)

A data table titled 'Annual Number of Birth-Related or Method-Related Deaths Associated with Control of Fertility Per 100,000 Nonsterile Women by Fertility Control Method According to Age'. It lists death rates by age groups (15-19 to 40-44) for various fertility control methods including no fertility control, oral contraceptives for non-smokers and smokers, IUD, condom, diaphragm/spermicide, and periodic abstinence. Annotations clarify birth-related and method-related deaths.*

FDA Label Image

Logo (Logo)

FDA Label Image

Structure (Structure)

Chemical structures of the active ingredients Norethindrone Acetate and Ethinyl Estradiol. The image shows two molecular diagrams side by side, each labeled with the corresponding compound name.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.